Developer docs
API playgroundTry for free, no card

Search company profiles

Windham Capital Partners

Full company profile

uuid00q2x3d

Namestring
Windham Capital Partners
Legal namestring
Windham Capital Partners
Websiteurl
windhamcap.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Windham Capital Partners is a privately held, healthcare-focused venture capital firm headquartered at 500 Fifth Avenue in New York City. Founded in 2002 by Roger Fine (former corporate vice president and general counsel of Johnson & Johnson) and Joe Proto, and previously operating as Windham Venture Partners, the firm invests in and supports healthcare technology companies commercializing innovations across medical devices, diagnostics, digital health, and biopharmaceuticals. Its portfolio includes PainTEQ, Valera Health, Clever Care Health Plan, TailorMed, Neuspera Medical, ChromaCode, Alto Neuroscience, CVRx, and Upward Health, with realized exits to strategic acquirers including Hologic, Olympus, Stryker, and Conmed.

The firm does not develop proprietary technology products; instead, it delivers value through capital, board-level governance, and an extensive healthcare network spanning pharmaceutical, medical device, and digital health markets. Windham's team of approximately 15+ individuals includes Co-Founders and General Partners (Adam Fine as CEO, Roger Fine as Chairman, Joe Proto), a Managing Partner (David Kereiakes, joined 2023 from Providence Ventures), Operating Partners (Jason Helgerson, Alistair Erskine), and senior advisors drawn from UnitedHealth Group, MIT, Emory Healthcare, Mass General Brigham, and the Robert Wood Johnson Foundation.

Windham generates revenue through traditional venture capital economics — management fees (typically 1.5–2% of committed capital) and carried interest (20% of profits above the hurdle rate) — sourced from institutional limited partners including family offices and foundations. The firm raises successive funds from these LPs and deploys capital via direct equity investments into healthcare technology companies, typically structured as seed-to-growth equity rounds. Its go-to-market is relationship-driven, with deal flow sourced through proprietary networks anchored by Providence, the AO Foundation, and the Robert Wood Johnson Foundation rather than through external marketing channels.

Short descriptiontext

Windham Capital Partners is a New York-based, healthcare-focused venture capital firm that invests in and provides strategic support to medical device, diagnostics, digital health, and biopharmaceutical companies for institutional limited partners and healthcare entrepreneurs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, healthtech investment, medical device investing, digital health venture, growth equity funding
Industry2 codes
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory
NAICS code1 code
  • All Other Financial Investment Activities52399
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeSubscription Recurring
Description

Generates revenue through traditional venture capital economics including management fees (typically 1.5-2% of committed capital) and carried interest (20% of profits above the hurdle rate) from successful portfolio company exits.

windhamcap.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components2 values
Personnel, Operations
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Windham Capital Partners is a healthcare-focused venture capital firm that invests in and supports HealthTech companies commercializing disruptive medical devices, diagnostics, digital health, and biopharmaceutical technologies. The firm raises capital from institutional limited partners and deploys it into portfolio companies, providing strategic guidance, board-level support, and access to extensive healthcare industry networks through the full investment lifecycle from due diligence to exit.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • $1 billion+ in realized returns from healthcare investments
Product overview1 text field

Windham Capital Partners is a healthcare venture capital firm that invests in HealthTech companies. Rather than offering a traditional product or service, the firm provides investment capital, strategic partnerships, and operational support to portfolio companies developing medical devices, diagnostics, digital health, and biopharmaceutical technologies. The firm focuses on companies that are commercializing technologies to improve healthcare outcomes and lower costs, with a portfolio spanning areas including cancer diagnostics, mental health treatments, neuromodulation, surgical imaging, and healthcare delivery optimization.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-11
Description

Windham's Managing Partner David Kereiakes joined the AO Foundation's Technology Transfer Board, which supports surgeon-led translation activities to bridge clinically validated medical innovations with broader patient access.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Providence is an integrated delivery network with 52 hospitals and 1,085 clinics serving over 5 million unique patients. Sara Vaezy, Providence's EVP and Chief Strategy and Digital Officer, serves as an advisor to Windham. Providence has collaborated with Windham portfolio companies including Valera Health.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

David Kereiakes, Managing Partner of Windham Capital Partners, was appointed to the AO Foundation's Technology Transfer Board in 2026. The AO Foundation operates the world's largest trauma and orthopedic surgical network spanning over 160 countries, focused on translating surgical innovation into patient impact.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Roger Fine serves as Chairman of the Board of Trustees of the Robert Wood Johnson Foundation, the 3rd largest foundation in the U.S. and the largest foundation in the world devoted to healthcare.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Healthcare-focused venture firm investing in biopharma, medtech, and digital health across stages. Comparable as a vertical specialist with similar deal types and exit pathways.

TypeDirect peer
Description

Healthcare-dedicated investment firm spanning venture through growth across biopharma, medtech, diagnostics, and digital health. Closest comparable to Windham in pure healthcare specialization and stage breadth.

TypeDirect peer
Description

Healthcare and technology venture capital firm with deep healthcare investing practice across medical devices, diagnostics, and digital health. Comparable as a multi-stage, healthcare-leaning specialist.

TypeBroad incumbent
Description

Large multi-stage VC with a dedicated Health Assurance thesis overlapping Windham's value-based care and digital health exposure. Comparable in healthcare deal types but materially larger and broader.

TypeDirect peer
Description

Early-stage life sciences venture firm focused on biotech, medtech, and research-platform companies. Comparable as a healthcare-only specialist with scientific founder relationships.

TypeDirect peer
Description

Sector-focused early-stage investor in science and medicine, including medical devices, diagnostics, and biotech. Comparable as a long-tenured healthcare specialist with similar deal sourcing from research institutions.

TypeDirect peer
Description

Healthcare-focused venture and growth equity firm investing in biopharma, medical devices, and healthcare IT. Comparable as a healthcare-only, multi-stage investor.

TypeBroad incumbent
Description

Large generalist VC with a dedicated bio/health fund investing across healthcare stages. Overlaps with Windham in healthcare investing but operates as part of a much broader portfolio across sectors.

TypeDirect peer
Description

Healthcare and technology venture firm (Fidelity-affiliated) investing across biotech, medtech, and health IT. Comparable as a sector-focused VC with similar portfolio breadth and stage range.

TypeDirect peer
Description

Dedicated healthcare investment firm providing venture and growth capital across biopharma, medtech, and healthcare services. Closely comparable business model and healthcare-only focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Windham Capital Partners

Healthcare Venture Capitalwindhamcap.com

Windham Capital Partners is a New York-based, healthcare-focused venture capital firm that invests in and provides strategic support to medical device, diagnostics, digital health, and biopharmaceutical companies for institutional limited partners and healthcare entrepreneurs.

What Windham Capital Partners does

Windham Capital Partners is a privately held, healthcare-focused venture capital firm headquartered at 500 Fifth Avenue in New York City. Founded in 2002 by Roger Fine (former corporate vice president and general counsel of Johnson & Johnson) and Joe Proto, and previously operating as Windham Venture Partners, the firm invests in and supports healthcare technology companies commercializing innovations across medical devices, diagnostics, digital health, and biopharmaceuticals. Its portfolio includes PainTEQ, Valera Health, Clever Care Health Plan, TailorMed, Neuspera Medical, ChromaCode, Alto Neuroscience, CVRx, and Upward Health, with realized exits to strategic acquirers including Hologic, Olympus, Stryker, and Conmed.

The firm does not develop proprietary technology products; instead, it delivers value through capital, board-level governance, and an extensive healthcare network spanning pharmaceutical, medical device, and digital health markets. Windham's team of approximately 15+ individuals includes Co-Founders and General Partners (Adam Fine as CEO, Roger Fine as Chairman, Joe Proto), a Managing Partner (David Kereiakes, joined 2023 from Providence Ventures), Operating Partners (Jason Helgerson, Alistair Erskine), and senior advisors drawn from UnitedHealth Group, MIT, Emory Healthcare, Mass General Brigham, and the Robert Wood Johnson Foundation.

Windham generates revenue through traditional venture capital economics — management fees (typically 1.5–2% of committed capital) and carried interest (20% of profits above the hurdle rate) — sourced from institutional limited partners including family offices and foundations. The firm raises successive funds from these LPs and deploys capital via direct equity investments into healthcare technology companies, typically structured as seed-to-growth equity rounds. Its go-to-market is relationship-driven, with deal flow sourced through proprietary networks anchored by Providence, the AO Foundation, and the Robert Wood Johnson Foundation rather than through external marketing channels.

Windham Capital Partners firmographics

Firmographics
Name
Windham Capital Partners
Legal name
Windham Capital Partners
Website
https://windhamcap.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
Windham Capital Partners is a New York-based, healthcare-focused venture capital firm that invests in and provides strategic support to medical device, diagnostics, digital health, and biopharmaceutical companies for institutional limited partners and healthcare entrepreneurs.
Ownership category
akta.pro rank

Windham Capital Partners industry classification

Industry
Product category
Healthcare Venture Capital
NAICS
All Other Financial Investment Activities (52399)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAD
Sector-Focused Venture Capital (Vertical Specialists)
SECONDARYBPAHADAB
Corporate Finance & Capital Advisory

Keywords

  • Healthcare venture capital
  • Healthtech investment
  • Medical device investing
  • Digital health venture
  • Growth equity funding

Where Windham Capital Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Windham Capital Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations

Revenue model

  1. Fund Management: Generates revenue through traditional venture capital economics including management fees (typically 1.5-2% of committed capital) and carried interest (20% of profits above the hurdle rate) from successful portfolio company exits.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Windham Capital Partners product offering

Product offering

Core offering

Windham Capital Partners is a healthcare-focused venture capital firm that invests in and supports HealthTech companies commercializing disruptive medical devices, diagnostics, digital health, and biopharmaceutical technologies. The firm raises capital from institutional limited partners and deploys it into portfolio companies, providing strategic guidance, board-level support, and access to extensive healthcare industry networks through the full investment lifecycle from due diligence to exit.

Product overview

Windham Capital Partners is a healthcare venture capital firm that invests in HealthTech companies. Rather than offering a traditional product or service, the firm provides investment capital, strategic partnerships, and operational support to portfolio companies developing medical devices, diagnostics, digital health, and biopharmaceutical technologies. The firm focuses on companies that are commercializing technologies to improve healthcare outcomes and lower costs, with a portfolio spanning areas including cancer diagnostics, mental health treatments, neuromodulation, surgical imaging, and healthcare delivery optimization.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • $1 billion+ in realized returns from healthcare investments

Companies that use Windham Capital Partners

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Windham Capital Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Windham Capital Partners partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • AO Foundation Technology Transfer BoardcoreStrategic or Co-development Partner · 11 May 2026Windham's Managing Partner David Kereiakes joined the AO Foundation's Technology Transfer Board, which supports surgeon-led translation activities to bridge clinically validated medical innovations with broader patient access.
  • ProvidencecoreStrategic or Co-development PartnerProvidence is an integrated delivery network with 52 hospitals and 1,085 clinics serving over 5 million unique patients. Sara Vaezy, Providence's EVP and Chief Strategy and Digital Officer, serves as an advisor to Windham. Providence has collaborated with Windham portfolio companies including Valera Health.
  • AO FoundationcoreStrategic or Co-development PartnerDavid Kereiakes, Managing Partner of Windham Capital Partners, was appointed to the AO Foundation's Technology Transfer Board in 2026. The AO Foundation operates the world's largest trauma and orthopedic surgical network spanning over 160 countries, focused on translating surgical innovation into patient impact.
  • Robert Wood Johnson FoundationcoreStrategic or Co-development PartnerRoger Fine serves as Chairman of the Board of Trustees of the Robert Wood Johnson Foundation, the 3rd largest foundation in the U.S. and the largest foundation in the world devoted to healthcare.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Windham Capital Partners competitors and assessment

Company assessment

Direct peers

  • Versant Ventures: Healthcare-focused venture firm investing in biopharma, medtech, and digital health across stages. Comparable as a vertical specialist with similar deal types and exit pathways.
  • OrbiMed: Healthcare-dedicated investment firm spanning venture through growth across biopharma, medtech, diagnostics, and digital health. Closest comparable to Windham in pure healthcare specialization and stage breadth.
  • Venrock: Healthcare and technology venture capital firm with deep healthcare investing practice across medical devices, diagnostics, and digital health. Comparable as a multi-stage, healthcare-leaning specialist.
  • 5AM Ventures: Early-stage life sciences venture firm focused on biotech, medtech, and research-platform companies. Comparable as a healthcare-only specialist with scientific founder relationships.
  • ARCH Venture Partners: Sector-focused early-stage investor in science and medicine, including medical devices, diagnostics, and biotech. Comparable as a long-tenured healthcare specialist with similar deal sourcing from research institutions.
  • New Leaf Venture Partners: Healthcare-focused venture and growth equity firm investing in biopharma, medical devices, and healthcare IT. Comparable as a healthcare-only, multi-stage investor.
  • F-Prime Capital: Healthcare and technology venture firm (Fidelity-affiliated) investing across biotech, medtech, and health IT. Comparable as a sector-focused VC with similar portfolio breadth and stage range.
  • Frazier Healthcare Partners: Dedicated healthcare investment firm providing venture and growth capital across biopharma, medtech, and healthcare services. Closely comparable business model and healthcare-only focus.

Broad incumbents

  • General Catalyst: Large multi-stage VC with a dedicated Health Assurance thesis overlapping Windham's value-based care and digital health exposure. Comparable in healthcare deal types but materially larger and broader.
  • Andreessen Horowitz (a16z Bio/Health): Large generalist VC with a dedicated bio/health fund investing across healthcare stages. Overlaps with Windham in healthcare investing but operates as part of a much broader portfolio across sectors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Windham Capital Partners social profiles

Digital presence

Windham Capital Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Windham Capital Partners leadership team

Management profile

Number of profiles

Profiles16 records

Windham Capital Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Windham Capital Partners M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Windham Capital Partners

What does Windham Capital Partners do?

Windham Capital Partners is a healthcare-focused venture capital firm that invests in and supports HealthTech companies commercializing disruptive medical devices, diagnostics, digital health, and biopharmaceutical technologies. The firm raises capital from institutional limited partners and deploys it into portfolio companies, providing strategic guidance, board-level support, and access to extensive healthcare industry networks through the full investment lifecycle from due diligence to exit.

Is Windham Capital Partners a public or private company?

Windham Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Windham Capital Partners founded?

Windham Capital Partners was founded in 2002. It employs 1 to 10 people.

Where is Windham Capital Partners based?

Windham Capital Partners is headquartered in New York, United States, in the North America region.

How does Windham Capital Partners make money?

One revenue line is on record: fund Management.

Who are Windham Capital Partners's main competitors?

Direct peers on record are Versant Ventures, OrbiMed, Venrock, 5AM Ventures, ARCH Venture Partners, New Leaf Venture Partners, F-Prime Capital and Frazier Healthcare Partners. Broad incumbents are General Catalyst and Andreessen Horowitz (a16z Bio/Health).

Does Windham Capital Partners have an API?

No public API is recorded for Windham Capital Partners.

What industry is Windham Capital Partners in?

Windham Capital Partners's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of BPAHADAB, Corporate Finance & Capital Advisory. Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireWindham Capital Partners' David Kereiakes Joins AO Foundation Technology Transfer Board to Translate Surgical Innovation into Patient ImpactDavid Kereiakes, managing partner of Windham Capital Partners, has been appointed to the AO Foundation's Technology Transfer Board, joining a nonprofit organization that operates the world's largest trauma and orthopedic surgical network spanning over 160 countries. Kereiakes brings over 15 years of orthopedic and trauma investing experience with over $1 billion in realized returns, having backed companies including PainTEQ and OrthAlign. The appointment aims to help bridge the gap between clinically validated medical innovations and broader patient access by supporting the AO Foundation's surgeon-led translation activities.PR NewswirePainTEQ Secures Majority Growth Recapitalization Co-Led by Signet Healthcare Partners & Windham Capital PartnersPainTEQ announced a majority growth recapitalization co-led by Signet Healthcare Partners and Windham Capital Partners, with MVolution Partners also investing. The company's LinQ implant has been used in over 14,000 procedures. The investment will fund clinical studies and expand U.S. commercial presence.PR NewswireWindham Capital Partners Appoints Former New York Medicaid Director, Jason Helgerson, and Chief Digital Officer and Chief Information Officer of Emory University, Dr. Alistair Erskine, as Operating PaWindham Capital Partners announced the appointment of Jason Helgerson and Dr. Alistair Erskine as Operating Partners, both of whom previously served as long-time advisors to the firm. Helgerson previously oversaw New York's $70 billion Medicaid program as the state's Medicaid Director, while Dr. Erskine brings decades of digital health transformation experience from leading health systems including Mass General Brigham and Geisinger. The appointments are intended to enhance the firm's industry expertise and expand its network in healthcare innovation at the intersection of medical technology and digital health.Alternatives WatchWindham's new operating partners sharpen focus on digital healthcare innovationWindham Capital Partners added Jason Helgerson and Dr. Alistair Erskine as operating partners for its Healthnet growth equity operations. Helgerson previously served as New York's Medicaid Director, overseeing a $70 billion program, while Erskine is CIO at Emory University. Their appointment is expected to enhance the group's healthcare innovation expertise and network.Tech in AsiaIsraeli digital health startup secures $40m in equity, debtTailorMed, an Israeli digital health startup, raised $40 million in equity and debt, led by Windham Capital Partners. The round included a $12.5 million debt component from Poalim Tech, bringing total funding to $69 million across three rounds. The company's platform connects patients, providers, pharmacies, and pharmaceutical companies to manage prescription drug costs.PR NewswireWindham Capital Partners Named to Inc.'s 2024 Founder-Friendly Investors ListWindham Capital Partners, a New York-based healthtech growth equity firm focused on digital health and medical technology investments, was named to Inc. Magazine's 2024 Founder-Friendly Investors List. The list recognizes investors with successful track records of collaborating with and remaining actively involved in founder-led businesses. The firm emphasized its approach of providing not only capital but also strategic guidance, operational support, and network access to help founders navigate the healthcare and technology landscape.